REVATI SHREENIWAS
Medical Practice in Palo Alto, CA
License number
New Jersey 25MA05448800
Issued Date
Dec 3, 1990
Expiration Date
Jun 30, 1997
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Palo Alto, CA
Personal information
See more information about REVATI SHREENIWAS at radaris.comName
Address
Phone
3375 Alma St APT 377, Palo Alto, CA 94306
819 Sutter Ave, Palo Alto, CA 94303
819 Sutter Ave, Palo Alto, CA 94303
Professional information
Dr. Revati Shreeniwas, Palo Alto CA - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
819 Sutter Ave, Palo Alto 94303
(650) 723-4000 (Phone), (650) 723-4000 (Fax)
300 Pasteur Dr, Stanford 94305
(650) 498-7103 (Phone)
(650) 723-4000 (Phone), (650) 723-4000 (Fax)
300 Pasteur Dr, Stanford 94305
(650) 498-7103 (Phone)
Certifications:
Critical Care Medicine, 1995, Internal Medicine, 1989, Pulmonary Disease, 1994
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
819 Sutter Ave, Palo Alto 94303
300 Pasteur Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
300 Pasteur Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
University of Pune / Armed Forces Medical College
Worcester City Hosp
Columbia Coll P&S
University of Pune / Armed Forces Medical College
Worcester City Hosp
Columbia Coll P&S
Methods Of Use For Monomethyl Fumarate And Prodrugs Thereof
US Patent:
2014005, Feb 27, 2014
Filed:
Aug 22, 2013
Appl. No.:
13/973820
Inventors:
Peter A. Virsik - Portola Valley CA, US
Mark A. Gallop - Palo Alto CA, US
Kenneth C. Cundy - Redwood City CA, US
Dmitri V. Lissin - Santa Clara CA, US
Revati Shreeniwas - Palo Alto CA, US
Mark A. Gallop - Palo Alto CA, US
Kenneth C. Cundy - Redwood City CA, US
Dmitri V. Lissin - Santa Clara CA, US
Revati Shreeniwas - Palo Alto CA, US
Assignee:
XenoPort, Inc. - Santa Clara CA
International Classification:
C07C 69/60, C07D 265/30
US Classification:
5142392, 514547
Abstract:
Methods of therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.